UBS lowered the firm’s price target on Clorox (CLX) to $110 from $121 and keeps a Neutral rating on the shares. The firm thinks Q1 results for much of the consumer staples group will be “okay” as organic revenue growth will show signs of improvement and stabilization, though the issue centers on how companies will handle forward looking commentary as inflation is likely to pose a greater risk to earnings in the second half and potentially beyond, the analyst tells investors in a preview for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Balanced Risk-Reward on Clorox: Limited Near-Term Upside Despite GOJO-Driven Revenue Boost and ERP-Inflated Growth Comparisons
- Clorox Completes Acquisition of Purell Maker GOJO Industries
- Clorox completes acquisition of Gojo Industries
- Clorox price target lowered to $98 from $111 at TD Cowen
- Clorox price target lowered to $101 from $112 at Deutsche Bank
